lymph nodes of rats following chronic administration of the two compounds.
The poor immunosuppressive effect on cellmediated immunity, demonstrated by failure of ICRF 159 to increase significantly the survival of skin allografts, is being further investigated to see whether this lack of effect also applies to other manifestations of cell-mediated immunity such as delayed hypersensitivity and the graft-versus-host reaction. Preliminary results appear to indicate that the drug is more effectively immunosuppressive under these conditions. Suppression of cell-mediated immunity by anticancer agents may be of considerable clinical significance, since there is some evidence (James & Salsbury 1972 , Lewis et al. 1969 ) that the spread of strongly antigenic tumours may be controlled by this form of immunity. It seems possible, therefore, that where an anticancer agent is not successful in eliminating the last few cancer cells, but only depresses the mechanism that prevents their dissemination, spread of the disease may soon follow treatment.
Although ICRF 159 has, in common with most anticancer agents, an immunosuppressive effect, this is (a) only moderate on cell-mediated immunity and (b) counterbalanced by the fact that the drug itself has an antimetastatic effect by preventing the escape of malignant cells into the bloodstream.
Examination of the peripheral blood of mice following tumour implants has shown that considerable numbers of atypical mononuclear cells appear in the blood within 48 hours of tumour implantation (Salsbury, unpublished) . These cells are pyroninophilic, their appearance is inhibited by antithymocyte serum and the time course of their appearance is consistent with the assumption that they may be immunoblasts. They are greatly diminished in animals treated with ICRF 159.
Immunoblasts have been widely implicated as the effector cells for cell-mediated immunity in the homograft reaction and it may be that they also play a part in preventing the establishment of tumours and in controlling their spread. If they do, the depression of their numbers by ICRF 159 following tumour implantation contrasts strangely with the weak immunosuppressive effect of the drug on cell-mediated immunity following skin allograft transplantation. It leads one to suppose that there must be different populations of immunoblasts with differential sensitivities involved in cell-mediated immunity evoked by different types of antigens.
Professor Peter Alexander (Chester Beatty Research Institute, Belmont, Sutton, Surrey)
Immunosuppressive Action of L-Asparaginase
The discovery that the enzyme L-asparaginase is immunosuppressive followed directly from the use of this material in the treatment of acute leukiemia. Some leukaemia cells require exogenous asparagine for survival and hence the depletion of circulating asparagine by the administration of, L-asparaginase results in the death of these leukiemia cells. L-asparaginase seemed at one time to be the first truly specific antineoplastic agent, for no other cell renewal system, such as the bone marrow or the gastrointestinal mucosa, appeared to require exogenous asparagine for normal function. In practice, the administration of the enzyme L-asparaginase gave rise to toxic side-effects; these were not as serious as found with the normal cytotoxic agents and, in particular, unlike almost all other anticancer agents, there was no effect on the cells in the blood. The reason for this toxicity is not quite clear since the only practical source of L-asparaginase is from bacteria and it is with such preparations that the side-effects have been observed. The various bacterial L-asparaginases also have glutaminase activity and it is possible that some of the toxic side-effects are due to the hydrolysis of glutamine or to other effects following from the injection of large amounts of bacterial protein. In theory, this problem ought to be resolved by using L-asparaginase from mammalian sources and in particular from the serum of guinea-pigs or agoutis. In practice, it has not been possible to obtain sufficient mammalian enzyme for detailed studies in animals in vivo, let alone for clinical trial.
Very soon after L-asparaginase began to be given clinically, its immunosuppressive activity was detected by the fact that the Mantoux reaction became negative. The remarkable feature of this suppression was that it only occurred while L-asparaginase was being administered. Within a day or two of stopping the administration of L-asparaginase, the patient again gave positive tests. Detailed studies in man and in animals quickly showed that both humoral and cell-mediated immune reactions were suppressed by L-asparaginase and the fact that the suppression ceases shortly after stopping treatment (i.e. by the time the L-asparaginase has been eliminated from the body) was demonstrated very clearly by skin graft rejection in experimental animals. The length of time which the skin grafts remained was determined entirely by the length of administration of the enzyme. Apart from its temporary nature, the other striking feature of immunosuppression by L-asparaginase is that it occurs without any depletion in the number of circulating lymphocytes. From a practical point of view, the toxicity encountered in continuous administration probably limits the usefulness of L-asparaginase as an immunosuppressive agent.
Almost all the studies on immunosuppressive activity have been carried out with the bacterial enzyme and the possibility therefore remains that the glutaminase activity is in some way involved in immunosuppression. While this possibility cannot be completely excluded, it is made unlikely by the fact that glutaminase-free L-asparaginase separated from agouti serum is as effective as the bacterial enzyme in suppressing in vitro the blast transformation of lymphocytes in response to: (1) plant substances such as phytohmmagglutinin; (2) exposure to soluble antigens to which the lymphocyte donor had been immunized; and (3) culturing with lymphocytes from a genetically different donor. We have collected evidence to indicate that the mechanism by which L-asparaginase causes immunosuppression in vivo is by interference with the transformation oflymphocytes into immunoblasts in response to antigenic stimulation. Investigations in several systems have shown that an essential component in the genesis of both cellmediated and humoral immunity is the transformation of stimulated cells into immunoblasts. This can be demonstrated rather clearly by collecting these immunoblasts as they leave the efferent lymphatic of a stimulated node. If these immunoblasts are removed, no systemic immunity results. We have been able to demonstrate that L-asparaginase prevents in rats the formation of immunoblasts so long as the enzyme is given at approximately the same time as the antigen. We feel that the immunosuppressive action of L-asparaginase can be fully accounted for by its interference with the transformation of lymphocytes by antigen.
L-asparaginase does not interfere with lymphocyte proliferation from lymphoid stem cells, so that the rate of recovery from lymphopenia induced by whole body exposure to X-rays is not influenced by L-asparaginase. The transformation of a small lymphocyte to an immunoblast requires a complete reorganization of the cell and the development of protein synthetic capacity for the production of antibodies. It is an attractive hypothesis that the economy of the cell during this transition period demands that the endogenous synthesis of asparagine is interrupted and that the lymphocyte relies during transformation on receiving asparagine from other sites in the body. This hypothesis explains why L-asparaginase is able to suppress immunity without there being any effect on the lymphoid organs or on the level of circulating lymphocytes. It also explains why the immunosuppressive action of Lasparaginase disappears within a day of stopping the administration of the enzyme.
[A full report of this work appears on p 189 Active immunotherapy is the stimulation, specific or not, of the cancer patient's immune defences. Our experiments (see Mathe 1971) suggested that active immunotherapy is best applied to a patient when he is carrying the smallest possible number of leukemic cells. To achieve this, we reduce the cell number by chemotherapy to in-
